Gallo Enrico, Rosa Elisabetta, Diaferia Carlo, Rossi Filomena, Tesauro Diego, Accardo Antonella
IRCCS SDN Via E. Gianturco 113 80143 Napoli Italy.
Department of Pharmacy, Research Centre on Bioactive Peptides (CIRPeB), University of Naples "Federico II" Via Mezzocannone 16 80134-Naples Italy
RSC Adv. 2020 Jul 21;10(45):27064-27080. doi: 10.1039/d0ra03194a. eCollection 2020 Jul 15.
Magnetic resonance imaging (MRI) is a well-known diagnostic technique used to obtain high quality images in a non-invasive manner. In order to increase the contrast between normal and pathological regions in the human body, positive (T1) or negative (T2) contrast agents (CAs) are commonly intravenously administered. The most efficient class of T1-CAs are based on kinetically stable and thermodynamically inert gadolinium complexes. In the last two decades many novel macro- and supramolecular CAs have been proposed. These approaches have been optimized to increase the performance of the CAs in terms of the relaxivity values and to reduce the administered dose, decreasing the toxicity and giving better safety and pharmacokinetic profiles. The improved performances may also allow further information to be gained on the pathological and physiological state of the human body. The goal of this review is to report a systematic overview of the nanostructurated CAs obtained and developed by manipulating soft materials at the nanometer scale. Specifically, our attention is centered on recent examples of fibers, hydrogels and nanogel formulations, that seem particularly promising for overcoming the problematic issues that have recently pushed the European Medicines Agency (EMA) to withdraw linear CAs from the market.
磁共振成像(MRI)是一种众所周知的诊断技术,用于以非侵入性方式获取高质量图像。为了增加人体正常区域和病理区域之间的对比度,通常静脉注射阳性(T1)或阴性(T2)造影剂(CAs)。最有效的T1造影剂类别基于动力学稳定且热力学惰性的钆配合物。在过去二十年中,人们提出了许多新型的大分子和超分子造影剂。这些方法已经得到优化,以提高造影剂在弛豫率值方面的性能,并减少给药剂量,降低毒性,提供更好的安全性和药代动力学特征。性能的改善还可能使人们获得关于人体病理和生理状态的更多信息。本综述的目的是系统概述通过在纳米尺度上操纵软材料而获得和开发的纳米结构化造影剂。具体而言,我们的注意力集中在纤维、水凝胶和纳米凝胶制剂的最新实例上,这些实例似乎特别有希望克服最近促使欧洲药品管理局(EMA)将线性造影剂撤出市场的问题。